Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?

Thura Win Htut, Kyaw Zin Thein, Kyaw Lwin Aung, Thein Hlaing Oo

Research output: Contribution to journalArticlepeer-review

Abstract

Thrombosis is the second leading cause of death in cancer patients. Patients with pancreatic cancer (PC) have a very high risk of developing venous thromboembolism (VTE). Even though primary ambulatory thromboprophylaxis (PATP) could decrease this risk, there are uncertain issues with regard to the choice and dose of anticoagulants, duration of anticoagulant therapy, and patient selection criteria. In addition, the current practice guidelines on PATP in PC patients are equivocal. This review critically appraises the evidence on the use of PATP in PC patients receiving chemotherapy.

Original languageEnglish (US)
JournalSupportive Care in Cancer
DOIs
StateAccepted/In press - 2022

Keywords

  • Chemotherapy
  • Pancreatic cancer
  • Primary ambulatory thromboprophylaxis
  • Risk scoring systems
  • Venous thromboembolism

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?'. Together they form a unique fingerprint.

Cite this